Original Article

You have full text access to this OnlineOpen article

A pilot study of high-dose intraarterial cisplatin chemotherapy with concomitant accelerated radiotherapy for patients with previously untreated T4 and selected patients with T3N0–N3M0 squamous cell carcinoma of the upper aerodigestive tract†

  1. Robert L. Foote M.D.1,‡,*,
  2. Jan L. Kasperbauer M.D.2,
  3. Scott H. Okuno M.D.3,
  4. Douglas A. Nichols M.D.4,
  5. Kerry D. Olsen M.D.2,
  6. Paul D. Brown M.D.1,
  7. Yolanda I. Garces M.D.1,
  8. Daniel J. Sargent Ph.D.5,
  9. Scott E. Strome M.D.2

Article first published online: 13 DEC 2004

DOI: 10.1002/cncr.20803

Issue

Cancer

Cancer

Volume 103, Issue 3, pages 559–568, 1 February 2005

Additional Information

How to Cite

Foote, R. L., Kasperbauer, J. L., Okuno, S. H., Nichols, D. A., Olsen, K. D., Brown, P. D., Garces, Y. I., Sargent, D. J. and Strome, S. E. (2005), A pilot study of high-dose intraarterial cisplatin chemotherapy with concomitant accelerated radiotherapy for patients with previously untreated T4 and selected patients with T3N0–N3M0 squamous cell carcinoma of the upper aerodigestive tract. Cancer, 103: 559–568. doi: 10.1002/cncr.20803

Author Information

  1. 1

    Division of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota

  2. 2

    Department of Otorhinolaryngology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota

  3. 3

    Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota

  4. 4

    Department of Radiology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota

  5. 5

    Division of Biostatistics, Mayo Clinic and Mayo Foundation, Rochester, Minnesota

  1. ‡

    Fax: (507) 284-0079

*Division of Radiation Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905

  1. †

    See related editorial on pages 447–50, this issue.

Publication History

  1. Issue published online: 20 JAN 2005
  2. Article first published online: 13 DEC 2004
  3. Manuscript Accepted: 23 AUG 2004
  4. Manuscript Revised: 5 AUG 2004
  5. Manuscript Received: 27 APR 2004

Funded by

  • National Cancer Institute. Grant Number: CA-15083

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (136K)

REFERENCES

  • 1
    Rooney M, Kish J, Jacobs J, et al M. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer. 1985; 55: 1123–1128.
    Direct Link:
  • 2
    Dreyfuss AI, Clark JR, Wright JE, et al. Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated Stage IV carcinoma of the head and neck. Ann Int Med. 1990; 112: 167–172.
  • 3
    Wolf GT, Hong WK, Fisher SG, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991; 324: 1685–1690.
  • 4
    Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998; 338: 1798–1804.
  • 5
    Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999; 91: 2081–2086.
  • 6
    Weissberg JB, Son YH, Papac RJ, et al. Randomized clinical trial of mitomycin-C as an adjunct to radiotherapy in head and neck cancer. Int J Radiat Oncol Biol Phys. 1989; 17: 3–9.
  • 7
    Bachaud JM, David JM, Boussin G, Daly N. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced squamous cell carcinoma of the head and neck: preliminary report of a randomized trial. Int J Radiat Oncol Biol Phys. 1991; 20: 243–246.
  • 8
    Eckman WW, Patlak CS, Fenstermacher JD. A critical evaluation of the principles governing the advantages of intra-arterial infusions. J Pharmokinet Biopharmaceut. 1974; 2: 257–285.
  • 9
    Shea M, Koziol JA, Howell SB. Kinetics of sodium thiosulfate, a cisplatin neutralizer. Clin Pharmacol Ther. 1984; 35: 419–425.
  • 10
    Umeki S, Kuninori T, Niro O, et al. Urinastatin (kunitz-type proteinase inhibitor) reducing cisplatin nephrotoxicity. Am J Med Sci. 1989; 289: 221–226.
  • 11
    Elfernick F, Van der Vijgh WJF, Klein I, Pinendo HM. Interaction of cisplatin with sodium thiosulfate: reaction rates and protein binding. Clin Chem. 1986; 32: 641–645.
  • 12
    Miner WD, Sanger GJ. Inhibition of cisplatin induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol. 1986; 88: 497–499.
  • 13
    Howell SB. Pharmacokinetic principles of regional chemotherapy. Contrib. Oncol. 1988; 29: 1–8.
  • 14
    Elferink WJF, van der Vifah IK, Pinedo HM. Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding. Clin Chem. 1986; 32: 642–645.
  • 15
    Howell SB, Taetle R. The effect of sodium thiosulfate on cis-dichlorodaimminedplatin (II) nephrotoxicity and antitumor activity in the L1210 leukemia. Cancer Treat Rep. 1980; 64: 611–615.
  • 16
    Robbins KT, Storniolo AM, Kerber C. Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. J Clin Oncol. 1994; 12: 2113–2120.
  • 17
    Robbins KT, Storniolo AM, Hryniuk WM, Howell SB. “Decadose” effects of cisplatin on squamous cell carcinoma of the upper aerodigestive tract. II. Clinical studies. Laryngoscope. 1996; 106: 37–42.
    Direct Link:
  • 18
    Robbins KT, Vicario D, Seagren S, et al. A targeted supradose cisplatin chemoradiation protocol for advanced head and neck cancer. Am J Surg. 1994; 168: 419–422.
  • 19
    Robbins KT, Fontanesi J, Wong FS, et al. A novel organ preservation protocol for advanced carcinoma of the larynx and pharynx. Arch Otolaryngol Head Neck Surg. 1996; 122: 853–857.
  • 20
    Weisman RA, Christen RD, Jones VE, et al. Observations on control of N2 and N3 neck disease in squamous cell carcinoma of the head and neck by intra-arterial chemoradiation. Laryngoscope. 1998; 108: 800–805.
    Direct Link:
  • 21
    Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000; 48: 7–16.
  • 22
    FlemingID, CooperJS, HensonDE, et al., editors. AJCC cancer staging manual, 5th ed. Philadelphia: Lippincott-Raven, 1997.
  • 23
    Robbins KT, Kumar P, Wong FSH, et al. Targeted chemoradiation for advanced head and neck cancer: analysis of 213 patients. Head Neck. 2000; 22: 687–693.
    Direct Link:
  • 24
    Kaplan E. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1953; 53: 475–481.
  • 25
    Robbins KT, Storniolo AM, Kerber C, et al. Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. J Clin Oncol. 1994; 12: 2113–2020.
  • 26
    Robbins KT, Vicario D, Seagren S, et al. A targeted supradose cisplatin chemoradiation protocol for advanced head and neck cancer. Am J Surg. 1994; 168: 419–422.
  • 27
    Robbins KT, Fontanesi J, Wong FS, et al. A novel organ preservation protocol for advanced carcinoma of the larynx and pharynx. Arch Otolaryngol Head Neck Surg. 1996; 122: 853–857.
  • 28
    Robbins KT, Kumar P, Regine WF, et al. Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: the Memphis experience. Int J Radiat Oncol Biol Phys. 1997; 38: 263–271.
  • 29
    Samant S, Kumar P, Wan J, et al. Concomitant radiation therapy and targeted cisplatin chemotherapy for the treatment of advanced pyriform sinus carcinoma: disease control and preservation of organ function. Head Neck. 1999; 21: 595–601.
    Direct Link:
  • 30
    Ahmed KA, Robbins KT, Wong F, Salazar JE. Efficacy of concomitant chemoradiation and surgical salvage for N3 nodal disease associated with upper aerodigestive tract carcinoma. Laryngoscope. 2000; 110: 1789–1793.
    Direct Link:
  • 31
    Samant S, Robbins KT, Kumar P, Ma JZ, Vieira F, Hanchett C. Bone or cartilage invasion by advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2001; 127: 1451–1456.
  • 32
    Balm AJM, Rasch CRN, Schornagel JH, et al. High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer. Head Neck. 2004; 26: 485–493.
    Direct Link:
  • 33
    Regine WF, Valentino J, Arnold SM, et al. High-dose intra-arterial cisplatin boost with hyperfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2001; 19: 3333–3339.
  • 34
    Wilson WR, Siegel RS, Harisiadis LA, Davis DO, Nguyen HN, Bank WO. High-dose intra-arterial cisplatin therapy followed by radiation therapy for advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2001; 127: 809–812.
  • 35
    Murry T, Madasu R, Martin A, Robbins KT. Acute and chronic changes in swallowing and quality of life following intraarterial chemoradiation for organ preservation in patients with advanced head and neck cancer. Head Neck. 1998; 20: 31–37.
    Direct Link:
  • 36
    Ackerstaff AH, Tan IB, Rasch CRN, et al. Quality-of-life assessment after supradose selective intra-arterial cisplatin and concomitant radiation (RADPLAT) for inoperable Stage IV head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2002; 128: 1185–1190.
  • 37
    Graner DE, Foote RL, Kasperbauer JL, et al. Swallow function in patients pre and post intraarterial chemoradiation. Laryngoscope. 2003; 113: 573–579.
    Direct Link:
View Full Article (HTML) Get PDF (136K)